ESC CONGRESS 2014

30 August - 03 September 2014, Barcelona - Spain

Session Details

Poster session 6: Thrombosis and anticoagulation - II
Tue 02 Sep 08:30 - 12:30 Thrombosis and coagulation Poster Session Poster area - Central Village

Access slides, videos, reports online via ESC Congress 365 Other resources

List of Presentations

Time
 
FP Nr
 
Title
 
Speakers
 
Related documents
08:30P5518Rivaroxaban in patients after an acute coronary syndrome with cardiac biomarker elevation: insights from the ATLAS ACS 2-TIMI 51 trialJessica MEGA (Boston, US)
08:30P5519Cancer associated microthrombosis; a contributing factor to troponin elevation in acute ischemic strokeCharlotte THALIN (Stockholm, SE)
08:30P5520Rivaroxaban in elective percutaneous coronary intervention to treat stable coronary artery disease.Pascal VRANCKX (Hasselt, BE)
08:30P5521Incidence and predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysisClaudio MORETTI (Torino, IT)
08:30P5522Role of bivalirudin in radial coronary interventions: a meta-analysis of observational studiesFederico CONROTTO (Torino, IT)
08:30P5523Prothrombotic properties of Dabigatran-treated blood under flowTobias PETZOLD (Munich, DE)
08:30P5524No signal for higher risk of myocardial infarction with apixaban: meta-analysis of randomized controlled trialsAndras KOMOCSI (Pecs, HU)
08:30P5525Comparison of fondaparinux and enoxaparin for non ST elevation acute coronary syndromes - an evaluation in a real world populationPedro S MATEUS (V.N. Gaia, PT)
08:30P5526Novel oral anticoagulants (NOAC) show the anticoaglant action without excess suppression of thrombinYouichi KOBAYASHI (Tokyo, JP)
08:30P5527Apixaban for the treatment of venous thromboembolism in cancer patients: Data from the AMPLIFY trialGiancarlo AGNELLI (Perugia, IT)
08:30P5528Direct acting oral anticoagulants are more effective than Vitamin-K-antagonists for the resolution of established left atrial thrombi in patients with atrial fibrillation.Christoph HAMMERSTINGL (Bonn, DE)
08:30P5529Rivaroxaban inhibits angiotensin II-induced cardiac fibrosis via reduction of inflammatory cytokines production through the growth stimulating signal pathway.Takehiro HASHIKATA (Sagamihara City, JP)